{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:13:01Z","timestamp":1780956781797,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica, Argentina","doi-asserted-by":"crossref","award":["PICT-2019-1623"],"award-info":[{"award-number":["PICT-2019-1623"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"crossref","award":["PIP-2232"],"award-info":[{"award-number":["PIP-2232"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06074-3","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T02:03:02Z","timestamp":1730944982000},"page":"5249-5260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune checkpoints PD1\/PDL1, TIM3\/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-6764","authenticated-orcid":false,"given":"Mar\u00eda Jazm\u00edn","family":"Toloza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-6538","authenticated-orcid":false,"given":"Marco","family":"Lincango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6148-7563","authenticated-orcid":false,"given":"Mar\u00eda Fernanda","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-2108","authenticated-orcid":false,"given":"Martin Manuel","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1983-6145","authenticated-orcid":false,"given":"Alicia","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Moiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8153-9728","authenticated-orcid":false,"given":"Fernanda","family":"Tosin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3545-0427","authenticated-orcid":false,"given":"Romina","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariel","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Negri","family":"Aranguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elisa","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-4265","authenticated-orcid":false,"given":"Irene B.","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5034-1055","authenticated-orcid":false,"given":"Carolina B.","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"issue":"16","key":"6074_CR1","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/cancers15164112","volume":"15","author":"E Abruzzese","year":"2023","unstructured":"Abruzzese E, Bocchia M, Trawinska MM et al (2023) Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-qPCR, d-PCR and CD26\u2009+\u2009stem cell measurements in chronic myeloid leukemia (CML) patients in Deep Molecular Response (DMR). Cancers 15(16):4112","journal-title":"Cancers"},{"key":"6074_CR2","doi-asserted-by":"crossref","unstructured":"Br\u00fcck O, Blom S, Dufva O, Leukemia et al (2018) 32(7), 1643\u20131656","DOI":"10.1038\/s41375-018-0175-0"},{"key":"6074_CR3","doi-asserted-by":"publisher","first-page":"1078118","DOI":"10.3389\/fimmu.2023.1078118","volume":"14","author":"D Yao","year":"2023","unstructured":"Yao D, Lai J, Lu Y et al (2023) Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment. Front Immunol 14:1078118","journal-title":"Front Immunol"},{"key":"6074_CR4","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","volume":"8","author":"A Hughes","year":"2017","unstructured":"Hughes A, Yong ASM (2017) Immune Effector Recovery in Chronic myeloid leukemia and treatment-free remission. Front Immunol 8:469","journal-title":"Front Immunol"},{"issue":"5","key":"6074_CR5","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","volume":"35","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Kirschner K, Copland M (2021) Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia 35(5):1229\u20131242","journal-title":"Leukemia"},{"issue":"1","key":"6074_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12935-023-02905-x","volume":"23","author":"FM Zhong","year":"2023","unstructured":"Zhong FM, Yao FY, Yang YL et al (2023) Molecular subtypes predict therapeutic responses and identifying and validating diagnostic signatures based on machine learning in chronic myeloid leukemia. Cancer Cell Int 23(1):61","journal-title":"Cancer Cell Int"},{"key":"6074_CR7","doi-asserted-by":"crossref","unstructured":"Huuhtanen J, Ilander M, Yadav B et al (2022) IFN-\u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Investig, 132(17), e152585","DOI":"10.1172\/JCI152585"},{"issue":"22","key":"6074_CR8","first-page":"2738","volume":"141","author":"V Krishnan","year":"2023","unstructured":"Krishnan V, Schmidt F, Nawaz Z et al (2023) A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia. Blood 141(22):2738\u20132755","journal-title":"Blood"},{"issue":"1","key":"6074_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","volume":"38","author":"J Huuhtanen","year":"2024","unstructured":"Huuhtanen J, Adnan-Awad S, Theodoropoulos J et al (2024) Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia 38(1):109\u2013125","journal-title":"Leukemia"},{"key":"6074_CR10","doi-asserted-by":"crossref","unstructured":"Christiansson L, S\u00f6derlund S, Svensson E et al (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS ONE, 8(1), e55818","DOI":"10.1371\/journal.pone.0055818"},{"key":"6074_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3389\/fonc.2015.00107","volume":"5","author":"C Giallongo","year":"2015","unstructured":"Giallongo C, Parrinello N, Brundo MV et al (2015) Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol 5:107","journal-title":"Front Oncol"},{"issue":"5","key":"6074_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"H Sun","year":"2015","unstructured":"Sun H, Li Y, Zhang ZF et al (2015) Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol 102(5):579\u2013586","journal-title":"Int J Hematol"},{"key":"6074_CR13","doi-asserted-by":"publisher","first-page":"146110","DOI":"10.1016\/j.gene.2021.146110","volume":"813","author":"MJ Toloza","year":"2022","unstructured":"Toloza MJ, Bestach Y, Lincango-Yupanki M et al (2022) Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy. Gene 813:146110","journal-title":"Gene"},{"issue":"2","key":"6074_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","volume":"129","author":"A Tarafdar","year":"2017","unstructured":"Tarafdar A, Hopcroft LE, Gallipoli P et al (2017) CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. Blood 129(2):199\u2013208","journal-title":"Blood"},{"issue":"1","key":"6074_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S (2017) Regulatory T cells in cancer immunotherapy. Cell Res 27(1):109\u2013118. https:\/\/doi.org\/10.1038\/cr.2016.151","journal-title":"Cell Res"},{"issue":"1","key":"6074_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nyas.13625","volume":"1417","author":"K Shitara","year":"2018","unstructured":"Shitara K, Nishikawa H (2018) Regulatory T cells: a potential target in cancer immunotherapy. Ann N Y Acad Sci 1417(1):104\u2013115","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"6074_CR17","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/s41598-021-97371-8","volume":"11","author":"I Harada","year":"2021","unstructured":"Harada I, Sasaki H, Murakami K et al (2021) Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. Sci Rep 11(1):18046","journal-title":"Sci Rep"},{"key":"6074_CR18","doi-asserted-by":"publisher","first-page":"106221","DOI":"10.1016\/j.leukres.2019.106221","volume":"86","author":"Y Bestach","year":"2019","unstructured":"Bestach Y, Toloza MJ, Ferri C et al (2019) The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib. Leuk Res 86:106221","journal-title":"Leuk Res"},{"issue":"8","key":"6074_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Sch\u00fcrch C, Schwaller J et al (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114(8):1528\u20131536","journal-title":"Blood"},{"key":"6074_CR20","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3389\/fimmu.2019.02493","volume":"10","author":"JS Almeida","year":"2019","unstructured":"Almeida JS, Couceiro P, L\u00f3pez-Sejas N et al (2019) NKT-Like (CD3\u2009+\u2009CD56+) cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Front Immunol 10:2493","journal-title":"Front Immunol"},{"issue":"9","key":"6074_CR21","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97(9):1236\u20131256","journal-title":"Am J Hematol"},{"issue":"4","key":"6074_CR22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984","journal-title":"Leukemia"},{"issue":"11","key":"6074_CR23","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1038\/leu.2016.197","volume":"30","author":"MS Ruiz","year":"2016","unstructured":"Ruiz MS, Medina M, Tapia I et al (2016) Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators. Leukemia 30(11):2258\u20132260","journal-title":"Leukemia"},{"issue":"6","key":"6074_CR24","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","volume":"26","author":"MW Pfaffl","year":"2004","unstructured":"Pfaffl MW, Tichopad A, Prgomet C et al (2004) Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper\u2013Excel-based tool using pair-wise correlations. Biotechnol Lett 26(6):509\u2013515","journal-title":"Biotechnol Lett"},{"issue":"4","key":"6074_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402\u2013408","journal-title":"Methods"},{"issue":"4","key":"6074_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","volume":"55","author":"SA Bustin","year":"2009","unstructured":"Bustin SA, Benes V, Garson JA et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611\u2013622","journal-title":"Clin Chem"},{"issue":"9","key":"6074_CR27","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","volume":"129","author":"A Hughes","year":"2017","unstructured":"Hughes A, Clarson J, Tang C et al (2017) CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood 129(9):1166\u20131176","journal-title":"Blood"},{"issue":"1","key":"6074_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","volume":"276","author":"M Das","year":"2017","unstructured":"Das M, Zhu C, Kuchroo VK (2017) Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev 276(1):97\u2013111","journal-title":"Immunol Rev"},{"issue":"1","key":"6074_CR29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jcmm.14825","volume":"24","author":"J Tao","year":"2020","unstructured":"Tao J, Han D, Gao S et al (2020) CD8\u2009+\u2009T cells exhaustion induced by myeloid-derived suppressor cells in myelodysplastic syndromes patients might be through TIM3\/Gal-9 pathway. J Cell Mol Med 24(1):1046\u20131058","journal-title":"J Cell Mol Med"},{"issue":"2","key":"6074_CR30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.18632\/oncotarget.6662","volume":"7","author":"L Pinton","year":"2016","unstructured":"Pinton L, Solito S, Damuzzo V et al (2016) Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget 7(2):1168\u20131184","journal-title":"Oncotarget"},{"issue":"3","key":"6074_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/JLB.5AB0121-041R","volume":"112","author":"A Cuccaro","year":"2022","unstructured":"Cuccaro A, Bellesi S, Galli E et al (2022) PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma. J Leukoc Biol 112(3):539\u2013545","journal-title":"J Leukoc Biol"},{"issue":"1","key":"6074_CR32","first-page":"2227494","volume":"28","author":"H Liu","year":"2023","unstructured":"Liu H, Dai Q, Li Y et al (2023) Association between high galectin expression and poor prognosis in hematologic cancers: a systematic review and meta-analysis. Hematol (Amsterdam Netherlands) 28(1):2227494","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"19","key":"6074_CR33","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","volume":"122","author":"P Gallipoli","year":"2013","unstructured":"Gallipoli P, Pellicano F, Morrison H et al (2013) Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation. Blood 122(19):3335\u20133339","journal-title":"Blood"},{"issue":"3","key":"6074_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.14740\/jh410w","volume":"7","author":"IB Hassan","year":"2018","unstructured":"Hassan IB, Benedict S, Kristensen J (2018) Cytokine syntheses by T-Cell subsets from chronic myeloid leukemia patients: relationship between pre-treatment levels and response to Imatinib Therapy. J Hematol 7(3):96\u2013106","journal-title":"J Hematol"},{"issue":"3","key":"6074_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162\u2013174","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"6074_CR36","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000458703","volume":"137","author":"P Ptackova","year":"2017","unstructured":"Ptackova P, Petrackova M, Hindos M et al (2017) Intracellular cytokines produced by stimulated CD3\u2009+\u2009cells from chronic myeloid leukemia patients. Acta Haematol 137(3):148\u2013157","journal-title":"Acta Haematol"},{"key":"6074_CR37","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","volume":"9","author":"AM Abel","year":"2018","unstructured":"Abel AM, Yang C, Thakar MS et al (2018) Natural killer cells: Development, Maturation, and clinical utilization. Front Immunol 9:1869","journal-title":"Front Immunol"},{"issue":"10","key":"6074_CR38","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","volume":"181","author":"N Larmonier","year":"2008","unstructured":"Larmonier N, Janikashvili N, LaCasse CJ et al (2008) Imatinib mesylate inhibits CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (Baltimore Md : 1950) 181(10):6955\u20136963","journal-title":"J Immunol (Baltimore Md : 1950)"},{"key":"6074_CR39","doi-asserted-by":"crossref","unstructured":"Chen P, Wang M, Li D et al (2015) The alteration and clinical significance of Th22\/Th17\/Th1 cells in patients with chronic myeloid leukemia. Journal of immunology research, 2015, 416123","DOI":"10.1155\/2015\/416123"},{"key":"6074_CR40","doi-asserted-by":"crossref","unstructured":"Giallongo C, Parrinello N, Tibullo D et al (2014) Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS ONE, 9(7), e101848","DOI":"10.1371\/journal.pone.0101848"},{"key":"6074_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.imlet.2016.09.004","volume":"179","author":"M Petrackova","year":"2016","unstructured":"Petrackova M, Hamsikova E, Duskova M et al (2016) Predictive value of serum cytokine levels in chronic myeloid leukemia patients. Immunol Lett 179:61\u201367","journal-title":"Immunol Lett"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06074-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06074-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:13:10Z","timestamp":1735866790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06074-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6074"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06074-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Academia Nacional de Medicina.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}